Citation Export
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bae, Yumi | - |
dc.contributor.author | Zeb, Alam | - |
dc.contributor.author | Choi, Ho Ik | - |
dc.contributor.author | Ryu, Jeong Su | - |
dc.contributor.author | Gul, Maleeha | - |
dc.contributor.author | Noh, Ha Yeon | - |
dc.contributor.author | Cho, Junho | - |
dc.contributor.author | Gil, Junkyung | - |
dc.contributor.author | Shah, Fawad Ali | - |
dc.contributor.author | Chang, Sun Young | - |
dc.contributor.author | Bae, Ok Nam | - |
dc.contributor.author | Kim, Jin Ki | - |
dc.date.issued | 2024-09-01 | - |
dc.identifier.issn | 2093-6214 | - |
dc.identifier.uri | https://aurora.ajou.ac.kr/handle/2018.oak/34033 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85188112287&origin=inward | - |
dc.description.abstract | Purpose: Dexamethasone palmitate (DXPL) is a lipophilic derivative of dexamethasone (DXM) used to overcome the low drug-loading capacity and immediate release characteristics of DXM from nanoparticles. In this study, we investigated the potential of DXPL-loaded solid lipid nanoparticles (DXPL-SLNs) to increase drug encapsulation efficiency, prolong drug release, and alleviate skin inflammation. Methods: DXPL-SLNs were prepared using the nano-emulsion template technique with trilaurin as a lipid matrix and Tween 20, Span 20, and Brij 58 as a surfactant mixture. The physicochemical properties of DXPL-SLNs were examined in terms of particle size, polydispersity index, zeta potential, encapsulation efficiency, loading capacity, morphology, and crystalline behavior. The in vitro release profile of DXM from the DXPL-SLNs incubated in mouse plasma was assessed using a plasma conversion assay. In vivo anti-inflammatory effects of topically applied DXPL-SLNs were evaluated in mice with 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced ear edema. Results: The optimized DXPL-SLNs (DXPL/trilaurin/Tween 20/Span 20/Brij 58:4/2/2/0.2/4, w/w ratio, respectively) displayed a mean particle size of 182.8 ± 2.7 nm with a very high drug loading capacity of 30.4%. DXPL-SLNs showed substantially prolonged drug release in mouse plasma compared to DXPL solution. Furthermore, DXPL-SLNs showed enhanced anti-inflammatory effects by efficiently reducing TPA-induced ear edema. Conclusion: These findings suggest that DXPL-SLNs have great potential as anti-inflammatory therapeutics against acute skin inflammation. | - |
dc.description.sponsorship | This work was supported by the Materials/Parts Technology Development Program (Development of industry process of a new hyaluronic acid, 200 Pa\u00b7s or more, of more than 20 times compared to the existing for sustained-release DDS, 1415184765, 20016715) funded by the Ministry of Trade, Industry and Energy (MOTIE, Korea). | - |
dc.language.iso | eng | - |
dc.publisher | Springer | - |
dc.title | High payload dexamethasone palmitate-loaded solid lipid nanoparticles for enhanced anti-inflammatory effects in acute skin inflammation model | - |
dc.type | Article | - |
dc.citation.endPage | 629 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 617 | - |
dc.citation.title | Journal of Pharmaceutical Investigation | - |
dc.citation.volume | 54 | - |
dc.identifier.bibliographicCitation | Journal of Pharmaceutical Investigation, Vol.54 No.5, pp.617-629 | - |
dc.identifier.doi | 10.1007/s40005-024-00674-x | - |
dc.identifier.scopusid | 2-s2.0-85188112287 | - |
dc.identifier.url | https://www.springer.com/journal/40005 | - |
dc.subject.keyword | Anti-inflammatory | - |
dc.subject.keyword | Dexamethasone | - |
dc.subject.keyword | Dexamethasone palmitate | - |
dc.subject.keyword | Ear edema | - |
dc.subject.keyword | Skin inflammation | - |
dc.subject.keyword | Solid lipid nanoparticles | - |
dc.type.other | Article | - |
dc.identifier.pissn | 2093-5552 | - |
dc.description.isoa | false | - |
dc.subject.subarea | Pharmaceutical Science | - |
dc.subject.subarea | Pharmacology, Toxicology and Pharmaceutics (miscellaneous) | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.